GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mind Medicine Inc (NAS:MNMD) » Definitions » ROE %
中文

Mind Medicine (Mind Medicine) ROE % : -109.65% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Mind Medicine ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Mind Medicine's annualized net income for the quarter that ended in Dec. 2023 was $-95.46 Mil. Mind Medicine's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $87.06 Mil. Therefore, Mind Medicine's annualized ROE % for the quarter that ended in Dec. 2023 was -109.65%.

The historical rank and industry rank for Mind Medicine's ROE % or its related term are showing as below:

MNMD' s ROE % Range Over the Past 10 Years
Min: -85.27   Med: -63.26   Max: -37.54
Current: -85.27

During the past 4 years, Mind Medicine's highest ROE % was -37.54%. The lowest was -85.27%. And the median was -63.26%.

MNMD's ROE % is ranked worse than
70.54% of 1361 companies
in the Biotechnology industry
Industry Median: -44.08 vs MNMD: -85.27

Mind Medicine ROE % Historical Data

The historical data trend for Mind Medicine's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mind Medicine ROE % Chart

Mind Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROE %
-44.73 -81.78 -37.54 -83.59

Mind Medicine Quarterly Data
Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.88 -70.58 -98.61 -71.00 -109.65

Competitive Comparison of Mind Medicine's ROE %

For the Biotechnology subindustry, Mind Medicine's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mind Medicine's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mind Medicine's ROE % distribution charts can be found below:

* The bar in red indicates where Mind Medicine's ROE % falls into.



Mind Medicine ROE % Calculation

Mind Medicine's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-95.732/( (150.917+78.134)/ 2 )
=-95.732/114.5255
=-83.59 %

Mind Medicine's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-95.456/( (95.979+78.134)/ 2 )
=-95.456/87.0565
=-109.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Mind Medicine  (NAS:MNMD) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-95.456/87.0565
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-95.456 / 0)*(0 / 133.0455)*(133.0455 / 87.0565)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.5283
=ROA %*Equity Multiplier
=N/A %*1.5283
=-109.65 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-95.456/87.0565
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-95.456 / -95.456) * (-95.456 / -88.82) * (-88.82 / 0) * (0 / 133.0455) * (133.0455 / 87.0565)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.0747 * N/A % * 0 * 1.5283
=-109.65 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Mind Medicine ROE % Related Terms

Thank you for viewing the detailed overview of Mind Medicine's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Mind Medicine (Mind Medicine) Business Description

Traded in Other Exchanges
Address
One World Trade Center, Suite 8500, New York, NY, USA, 10007
Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies.
Executives
Schond L. Greenway officer: Chief Financial Officer C/O CERECOR, INC., 540 GAITHER ROAD, SUITE 400, ROCKVILLE MD 20850
Robert Barrow director, officer: Chief Executive Officer C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Dan Karlin officer: Chief Medical Officer C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
David W Gryska director 749 N MARY AVE, SUNNYVALE CA 94085
Carol A Vallone director 490 SUMMER STREET, MANCHESTER MA 01944
Andreas Krebs director 5 GIRALDA FARMS, MADISON NJ 07940
Mark Sullivan officer: Chief Legal Officer 1000 BISHOPS GATE BOULEVARD, SUITE 300, MOUNT LAUREL NJ 08054
Suzanne Louise Bruhn director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Roger Crystal director 445 PARK AVE, 10TH FL., NEW YORK NY 10022
Cynthia W. Hu officer: Chief Legal Officer&Secretary 6440 WINDERMERE, NORTH BETHESDA MD 20852
Brigid Makes director 20245 SW 95TH AVENUE, TUALATIN OR 97062
Sarah Y Vinson director C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Stephen L Hurst director C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Miri Halperin Wernli director, officer: Executive President C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Carrie Liao officer: VP, Controller&Acct Principal C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007